Chimerix: Potential 'First' In Targeting Recurrent High-Grade Glioma Patients
Chimerix holds the potential to have the first approval of dordaviprone for treating recurrent H3 K27M mutant high-grade ...
60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split
Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that it will effect a 1-for-5 ...
Aspire Biopharma Holdings, Inc., Announces Public Listing on Nasdaq
The closing of the business combination with PowerUp Acquisition Corp. creates Nasdaq-listed biopharmaceutical company ...
FDA approves first rapid-acting insulin biosimilar for patients with diabetes
Aventis's Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with ...
Ionis Pharmaceuticals Reports Strong Q4 Earnings After Recent FDA Approval
Ionis Pharmaceuticals beats Q4 earnings, eyes sHTG market with TRYNGOLZA. Strong pipeline and cash position make it a ...
ophthalmologytimes2d
Alvotech and Teva Pharmaceuticals announce FDA accepts Biologics License Application for AVT06
Alvotech and Teva Pharmaceuticals announced the US Food and Drug Administration (FDA) has accepted for review a Biologics ...
MarketWatch4d
Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.
Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved the company’s non-opioid pain treatment. It’s the first new class ...
MedPage Today6d
FDA OKs First Rapid-Acting Insulin Biosimilar for Diabetes
The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and ...
Healio6d
FDA approves subcutaneous Merilog for glycemic control in diabetes
The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...
Dealbreaker on MSN6d
Aardvark Therapeutics’ Pursuit of New Obesity Target Adds $94M in IPO Cash
The biotech’s lead drug candidate is in Phase 3 testing in Prader-Willi syndrome, a genetic disorder that causes persistent hunger leading to overeating.
FiercePharma7d
Astellas' eye med Izervay lands key FDA label update, amping up market battle with Apellis rival
In the face of tough competition from Apellis and a recent setback with prescribers, Astellas’ geographic atrophy (GA) med ...